Fairfield Bush & CO. bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 500 shares of the biopharmaceutical company’s stock, valued at approximately $246,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Nomura Holdings Inc. purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $3,209,000. Raymond James Financial Services Advisors Inc. boosted its position in Regeneron Pharmaceuticals by 13.3% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 3,212 shares of the biopharmaceutical company’s stock valued at $1,578,000 after buying an additional 378 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Regeneron Pharmaceuticals by 1.2% in the second quarter. The Manufacturers Life Insurance Company now owns 84,977 shares of the biopharmaceutical company’s stock valued at $41,735,000 after buying an additional 1,037 shares during the last quarter. Cubist Systematic Strategies LLC boosted its position in Regeneron Pharmaceuticals by 176.1% in the second quarter. Cubist Systematic Strategies LLC now owns 671 shares of the biopharmaceutical company’s stock valued at $330,000 after buying an additional 428 shares during the last quarter. Finally, PointState Capital LP purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $78,199,000. Hedge funds and other institutional investors own 67.41% of the company’s stock.

WARNING: “Fairfield Bush & CO. Invests $246,000 in Regeneron Pharmaceuticals, Inc. (REGN) Stock” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.watchlistnews.com/fairfield-bush-co-invests-246000-in-regeneron-pharmaceuticals-inc-regn-stock/1623832.html.

In other news, CFO Robert E. Landry sold 189 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the completion of the sale, the chief financial officer now owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Michael S. Brown sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 89,468 shares of company stock valued at $42,312,448. Company insiders own 10.80% of the company’s stock.

A number of brokerages recently commented on REGN. Leerink Swann reiterated an “outperform” rating and issued a $573.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 22nd. Raymond James Financial, Inc. reissued an “outperform” rating and issued a $547.00 price target (up from $475.00) on shares of Regeneron Pharmaceuticals in a report on Thursday, June 22nd. BMO Capital Markets reissued a “market perform” rating and issued a $484.00 price target (up from $421.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Bank of America Corporation reissued a “buy” rating and issued a $593.00 price target (up from $589.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Finally, Sanford C. Bernstein downgraded Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating and boosted their price target for the company from $410.00 to $480.00 in a report on Monday, June 26th. They noted that the move was a valuation call. Three research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Regeneron Pharmaceuticals presently has an average rating of “Hold” and an average target price of $489.92.

Shares of Regeneron Pharmaceuticals, Inc. (REGN) traded down 2.00% during mid-day trading on Wednesday, reaching $451.92. The company’s stock had a trading volume of 364,998 shares. The firm has a market capitalization of $47.17 billion, a P/E ratio of 45.33 and a beta of 1.62. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $543.55. The company’s 50-day moving average is $460.12 and its 200 day moving average is $454.49.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the Zacks’ consensus estimate of $2.67 by $1.50. The business had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The business’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.82 earnings per share. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post $14.92 earnings per share for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.